CHP
CPRX

Cable Hill Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Cable Hill Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,000
Closed -$4K – 900
2017
Q4 		$4K Buy
+1,000
New +$3.3K ﹤0.01% 771

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cable Hill Partners's CPRX Position: Q1 2018 in Review

Cable Hill Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2018, closing a stake of 1,000 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in CPRX in Q4 2017 and held it in 1 quarter. The position peaked at $4K in Q4 2017. 98 funds tracked by Wall St. Rank hold CPRX as of Q1 2018.

  • Cable Hill Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 1,000 Catalyst Pharmaceutical shares in Q1 2018, an estimated $4K.
  • Cable Hill Partners first reported a position in Catalyst Pharmaceutical in Q4 2017 and held it in 1 quarter.
  • Cable Hill Partners's Catalyst Pharmaceutical position peaked at $4K in Q4 2017.
  • 98 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.